6505--Buspirone RFP
ID: 36E79725R0024Type: Presolicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/5afe89bd7bfd4be5802239be33321cd7/view
Timeline
  1. 1
    Posted Apr 3, 2025, 12:00 AM UTC
  2. 2
    Updated Apr 3, 2025, 12:00 AM UTC
  3. 3
    Due Apr 23, 2025, 7:30 PM UTC
Description

The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP 36E79725R0024) for the procurement of Buspirone HCL Tablets, which will serve the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). This unrestricted contract aims to ensure a consistent supply of various strengths of Buspirone HCL Tablets over a one-year period, with options for four additional one-year extensions, and requires offerors to provide the product's label name and a unique NDC number while adhering to specific packaging safety standards. The anticipated solicitation release date is April 8, 2025, with a response deadline set for April 23, 2025; interested parties should monitor the designated URL for updates, as no paper copies will be distributed. For inquiries, contact Amber Zavala at amber.zavala@va.gov or (708) 786-5245.

Point(s) of Contact
Amber.Zavala@va.govAmber Zavala
(708) 786-5245
amber.zavala@va.gov
Files
Title
Posted
36E79725R0024_1.docx
Apr 3, 2025, 8:05 PM UTC
The Presolicitation Notice from the VA National Acquisition Center outlines the intent to issue a Request for Proposal (RFP 36E79725R0024) for Buspirone HCL Tablets, intended for the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and Indian Health Service. This unrestricted procurement contract will cover a one-year period, with options for four additional one-year extensions. Offerors must provide consistent supply, state the product's label name, and possess a unique NDC number while ensuring packaging meets specified safety standards. The anticipated solicitation release date is April 8, 2025, with a response deadline set for April 23, 2025. The document mentions estimated annual needs for different sizes of Buspirone HCL Tablets, detailing quantities for each variant. Interested parties should monitor the specified URL for updates, as no paper copies will be distributed. Amber Zavala is the primary contact for this procurement.
Lifecycle
Title
Type
6505--Buspirone RFP
Currently viewing
Presolicitation
Similar Opportunities
6505--Topiramate Tablets (VA-25-00047941)
Buyer not available
The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Topiramate Tablets, designated as Solicitation 36E79725R0031. This procurement aims to secure an uninterrupted supply of various forms of Topiramate for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), highlighting the importance of ensuring continuous access to essential pharmaceuticals across federal health services. The contract will span one year with four additional pre-priced option years, and interested vendors must submit their proposals electronically by April 29, 2025, while providing the exact name of the drug along with a unique National Drug Code (NDC). For further inquiries, vendors can contact Contract Specialist Billy Fong at billy.fong@va.gov or by phone at 708-786-4992.
6505--Emtricitabine/Tenofovir Disoproxil Fumarate Tablets
Buyer not available
The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Emtricitabine 200mg/Tenofovir Disoproxil Fumarate 300mg Tablets, which will serve various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract aims to ensure an uninterrupted supply of this essential medication for a period of one year, with options for four additional one-year terms, emphasizing the VA's commitment to maintaining critical pharmaceutical supplies. The estimated annual requirement is approximately 91,583 bottles, and interested offerors must ensure their product has a unique National Drug Code (NDC) and complies with specific packaging requirements, including safety caps. The solicitation is expected to be issued electronically on or around April 26, 2025, with a response deadline of May 13, 2025; inquiries can be directed to Deb Fassl at Deborah.Fassl@va.gov.
6505--Ranolazine Sustained Action (SA) Tablets
Buyer not available
The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ranolazine Sustained Action (SA) Tablets, which will serve various federal entities, including the VA, Department of Defense, and Bureau of Prisons. The procurement aims to secure an uninterrupted supply of these pharmaceutical products, with specific requirements for labeling and packaging, including the necessity for a unique National Drug Code (NDC) and safety-cap standards. The estimated annual demand includes 229,028 bottles of 500 mg SA tablets and 95,925 bottles of 1000 mg SA tablets, with the contract expected to last one year, plus four optional one-year extensions. Interested offerors should monitor SAM.gov for updates and submit their proposals by May 6, 2025, with any inquiries directed to Contract Specialist Deb Fassl at Deborah.Fassl@va.gov.
6505--Perphenazine Tablets (VA-25-00037353)
Buyer not available
The Department of Veterans Affairs (VA) is soliciting proposals for the procurement of Perphenazine tablets under solicitation number VA-25-00037353. This contract aims to supply specified quantities of the drug to both the VA and the Department of Defense (DoD) through their Pharmaceutical Prime Vendor (PPV) Programs, with a focus on service-disabled veteran-owned small businesses, women-owned small businesses, and HUBZone small businesses. The procurement is critical for ensuring a consistent supply of pharmaceutical products while adhering to regulatory requirements, including the Drug Supply Chain Security Act (DSCSA) and FDA Good Manufacturing Practices (cGMP). Interested offerors must contact Contract Specialist Anthony DiCrescenzo at Anthony.DiCrescenzo@va.gov for further details, and proposals must include a 0.5% Cost Recovery Fee and a unique National Drug Code (NDC) for each product.
6505--Fludrocortisone Acetate Tablets (VA-25-00047932)
Buyer not available
The Department of Veterans Affairs is seeking offers for the procurement of Fludrocortisone Acetate Tablets (0.1 MG) under solicitation number 36E79725R0023, with an emphasis on compliance with federal regulations and pharmaceutical standards. Contractors are required to submit bids that include pricing for a base year and four option years, adhering to guidelines such as a 0.5% Cost Recovery Fee and compliance with the Drug Supply Chain Security Act. This procurement is crucial for ensuring a reliable supply of essential pharmaceuticals for veterans, reflecting the government's commitment to maintaining high standards in healthcare delivery. The deadline for submitting offers has been extended to April 21, 2025, at 2:30 PM Central Daylight Time, and interested parties should contact Contract Specialist Nicholas I McGregor at Nicholas.McGregor@va.gov for further information.
6505--Loperamide Capsules (VA-25-00032225)
Buyer not available
The Department of Veterans Affairs (VA) is seeking proposals for the procurement of Loperamide Hydrochloride (HCL) 2mg capsules, aimed at establishing a reliable supply source for pharmaceutical products to support healthcare services for veterans and other authorized users. Offerors must provide pricing for the base year and four additional one-year options, ensuring compliance with regulatory standards, including the Drug Supply Chain Security Act (DSCSA) and Good Manufacturing Practices (cGMP). This procurement is critical for maintaining the quality and safety of pharmaceutical distribution to VA facilities and the Department of Defense through a network of Prime Vendors. Proposals are due by April 23, 2025, at 2:30 PM Central Time, and interested parties should contact Contract Specialist Andrew J. Cazares at Andrew.Cazares@va.gov for further information.
Rizatriptan Benzoate
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
Dextroamphetamine - Amphetamine ER
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Dextroamphetamine - Amphetamine ER Capsules, specifically in dosages of 5 MG, 10 MG, 15 MG, 20 MG, 25 MG, and 30 MG, packaged in 100 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Bureau of Prisons, and Indian Health Service customers through DLA and VA prime vendor programs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be solicited as a commercial item under FAR part 12. Interested parties should monitor the DLA Bid Board System (DIBBS) and SAM.gov for the solicitation, projected for April 2025, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil.
Solifenacin
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Solifenacin, specifically 5MG and 10MG tablets in 30 and 90 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Indian Health Service, and Bureau of Prisons through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should direct inquiries to Jayne Do at jayne.do@dla.mil, with the solicitation anticipated to be posted in April 2025 on the DLA Bid Board System and SAM.gov.
Duloxetine HCL DR Capsules
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Duloxetine HCL DR Capsules, which includes various dosages and packaging options. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in April 2025. Interested parties should direct inquiries to Christopher Newman at christopher.newman@dla.mil or 445-737-7371, and are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates.